News | May 29, 2022
Venus Remedies registers 9.22 % growth in annual sales for FY22
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Subscribe To Our Newsletter & Stay Updated
